Biovotion

Biovotion, founded in Zurich, Switzerland, in 2011, specialized in wearable physiology monitoring, providing integrated solutions that included connected hardware and value-added services. The company was established by Dr. Andreas Caduff, an expert in non-invasive, wearable sensor technologies with a background in the pharmaceutical and medical device industries. His work focused on developing multisensor systems for wearable physiological monitoring, driven by the potential he saw in combining these devices with software ecosystems and machine learning.

The firm developed the Everion®, a clinical-grade, multi-sensor wearable device worn on the arm. This platform was designed to non-invasively measure 22 different parameters in real-time, such as heart rate, respiratory rate, blood oxygenation, and skin temperature. It also captured insights into sleep quality, energy expenditure, and stress levels. The data collected by the Everion device was integrated into a cloud platform, providing users with health data comparable to standard hospital monitoring systems. Biovotion's business model was centered on this combination of hardware, software, and services, forming a hybrid offering for continuous health monitoring both in clinical settings and at home. The company's clients included pharmaceutical companies, contract research organizations, and healthcare providers like the Mayo Clinic and the University Hospital of Basel.

A significant milestone in the company's history occurred in November 2019, when it was acquired by Biofourmis, a Boston-based digital therapeutics company. The acquisition included Biovotion's entire portfolio, featuring the Everion biosensor and over 60 global patents for wearable sensor technology. Following the acquisition, the Biovotion team was integrated into Biofourmis, operating under the new name Biofourmis AG in Zurich. This strategic move allowed Biofourmis to incorporate Biovotion's clinical-grade wearables into its own Biovitals® ecosystem, an AI-powered analytics platform that predicts clinical exacerbations. The integration aimed to create a comprehensive digital therapeutics solution for managing complex chronic conditions like heart failure, COPD, and oncology by combining continuous physiological data with predictive analytics. Keywords: Biovotion, Biofourmis, Everion, wearable physiology monitoring, digital health, medical-grade wearable, remote patient monitoring, biosensor, vital sign monitoring, Andreas Caduff, continuous monitoring, healthcare technology, clinical-grade sensor, digital therapeutics, physiological data, health analytics, chronic disease management, non-invasive monitoring, wearable sensor technology, AI health analytics, connected health, Biovitals, remote monitoring solutions